Similar articles

• Derivatives of R-aminocarnitine without ammonium moiety as liver carnitine palmitoyltransferase I (L-CPT I) inhibitors.

  Tassoni E, Conti R, Gallo G, Vincenti S, Mastrofrancesco L, Brunetti T, Cabri W, Giannessi F. Tassoni E, et al. ChemMedChem. 2011 Nov 4;6(11):1977-80. doi: 10.1002/cmdc.201100289. Epub 2011 Aug 10. ChemMedChem. 2011. PMID: 21834096 No abstract available.
• Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity.

  Giannessi F, Pessotto P, Tassoni E, Chiodi P, Conti R, De Angelis F, Dell'Uomo N, Catini R, Deias R, Tinti MO, Carminati P, Arduini A. Giannessi F, et al. J Med Chem. 2003 Jan 16;46(2):303-9. doi: 10.1021/jm020979u. J Med Chem. 2003. PMID: 12519067
• Reversible carnitine palmitoyltransferase inhibitors with broad chemical diversity as potential antidiabetic agents.

  Giannessi F, Chiodi P, Marzi M, Minetti P, Pessotto P, De Angelis F, Tassoni E, Conti R, Giorgi F, Mabilia M, Dell'Uomo N, Muck S, Tinti MO, Carminati P, Arduini A. Giannessi F, et al. J Med Chem. 2001 Jul 19;44(15):2383-6. doi: 10.1021/jm010889+. J Med Chem. 2001. PMID: 11448219
• Aminocarnitine and related compounds as inhibitors of carnitine transferases: physiologic implications.

  [No authors listed] [No authors listed] Nutr Rev. 1990 Jun;48(6):258-60. doi: 10.1111/j.1753-4887.1990.tb02952.x. Nutr Rev. 1990. PMID: 1365754 Review.
• Possible new therapeutic approach in diabetes mellitus by inhibition of carnitine palmitoyltransferase 1 (CPT1).

  Wolf HP. Wolf HP. Horm Metab Res Suppl. 1992;26:62-7. Horm Metab Res Suppl. 1992. PMID: 1490694 Review. No abstract available.